The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Pregnant mums and newborns will receive free vaccinations against respiratory syncytial virus (RSV) under the federal ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...

Beyfortus® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus® is also indicated for ...

This season will be the first time in Ontario that nirsevimab (sold under the brand name Beyfortus) is used to protect babies ...

Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning! For those who ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. ii BEYFORTUS® Product Monograph, Sanofi Pasteur Limited, June 14, 2024. iii ...